Protara Therapeutics (TARA) Cash from Operations (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Cash from Operations of 21343000.0 for Q1 2026, down 45.06% year-over-year from 38849382.53 in Q1 2025, and down 25.92% quarter-over-quarter from 16950000.0 in Q4 2025.
Powered by 
Analysis
Protara Therapeutics (TARA) Cash from Operations (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Cash from Operations for 14 consecutive years, with 21343000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 45.06% year-over-year to 21343000.0; the TTM figure through Mar 2026 stood at 62995000.0 (down 56.93% YoY), while the FY2025 annual figure was 56365000.0, down 57.41% from the prior year.
- Cash from Operations retreated to 21343000.0 in Q1 2026 per TARA's latest filing, from 16950000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 5026000.0 in Q4 2022 and bottomed at 21343000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 10442941.18 across 5 years, with a median of 9408000.0 in 2023.
- Annual changes were most pronounced in 2022 — Cash from Operations jumped 45.93% — and 2023, when it slumped 83.64%.
- Protara Therapeutics' Cash from Operations stood at 5026000.0 in 2022, then slumped by 73.1% to 8700000.0 in 2023, then slipped by 6.99% to 9308000.0 in 2024, then slumped by 82.1% to 16950000.0 in 2025, then dropped by 25.92% to 21343000.0 in 2026.
- Business Quant data shows TARA's Cash from Operations at 21343000.0 in Q1 2026, 16950000.0 in Q4 2025, and 12452000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Protara Therapeutics | 241.28 Mn | 241.28 Mn | - | -15.39 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15.39 Mn |
| Mar 31, 2026 | -21.34 Mn |
| Dec 31, 2025 | -16.95 Mn |
| Sep 30, 2025 | -12.45 Mn |
| Jun 30, 2025 | -12.25 Mn |
| Mar 31, 2025 | -14.71 Mn |
| Dec 31, 2024 | -9.31 Mn |
| Sep 30, 2024 | -8.43 Mn |
| Jun 30, 2024 | -7.69 Mn |
| Mar 31, 2024 | -10.38 Mn |
| Dec 31, 2023 | -8.70 Mn |
| Sep 30, 2023 | -6.56 Mn |
| Jun 30, 2023 | -9.41 Mn |
| Mar 31, 2023 | -12.89 Mn |
| Dec 31, 2022 | -5.03 Mn |
| Sep 30, 2022 | -5.35 Mn |
| Jun 30, 2022 | -5.12 Mn |
| Mar 31, 2022 | -10.96 Mn |
| Dec 31, 2021 | -6.91 Mn |
| Sep 30, 2021 | -6.20 Mn |